Paclitaxel for second-line treatment of squamous cell carcinoma of the head and neck:A multicenter retrospective Italian study  

作　　者：Morena Fasano Mario Pirozzi Pasquale Vitale Vincenzo Damiano Graziana Ronzino Stefano Farese Vincenzo Carfora Giuseppina Ciccarelli Ilaria Di Giovanni Sergio Facchini Gregorio Cennamo Michele Caraglia Fortunato Ciardiello Raffaele Addeo 

机构地区：[1]Division of Medical Oncology,Department of Precision Medicine,University of Campania Luigi Vanvitelli,Naples 80120,Italy [2]Oncology Operative Unit,Hospital of Frattamaggiore,ASL Napoli 2 Nord,Naples 80027,Italy [3]Department of Integrated Activities of Oncoematology,Diagnostica Per Immagini E Morfologica E Medicina Legale,Medical Oncology Unit,University Federico II,Naples 80120,Italy [4]Department of Oncology,Vito Fazzi Hospital,Lecce 73100,Italy [5]Department of Radiation Oncology,‘San Pio’Hospital,Benevento 82100,Italy [6]Department of Pharmacology,ASL Napoli 2 Nord,Naples 80020,Italy [7]Department of Precision Medicine,University of Campania Luigi Vanvitelli,Naples 80138,Italy [8]Laboratory of Precision and Molecular Oncology,Biogem Scarl,Institute of Genetic Research,Contrada Camporeale,Ariano Irpino,Avellino 83031,Italy

出　　处：《World Journal of Clinical Oncology》2024年第12期1468-1480,共13页世界临床肿瘤学杂志（英文）

摘　　要：BACKGROUND Squamous cell carcinoma of the head and neck(SCCHN)accounts for 3%of all malignant tumors in Italy.Immune checkpoint inhibitors combined with chemotherapy is first-line treatment for SCCHN;however,second-line treatment options are limited.Taxanes are widely used for combination therapy of SCCHN,as clinical trials have shown their efficacy in patients with this disease,partic ularly in patients with prior therapy.AIM To perform a multicenter retrospective study on the efficacy and safety of weekly paclitaxel for SCCHN.METHODS All patients were previously treated with at least one systemic therapy regimen,which included platinum-based therapy in the vast majority.No patient received prior immunotherapy.RESULTS Median progression-free survival(mPFS)was 3.4 months and median overall survival(mOS)was 6.5 months.Subgroup analysis was performed according to three principal prognostic factors:Smoking,alcohol consumption,and body mass index.Analysis demonstrated reduced survival,both mOS and mPFS,in the unfavorable prognostic groups,with the biggest deltas observed in mOS.CONCLUSION Weekly paclitaxel provided favorable survival and disease control rates,with low severe adverse events.Paclitaxel is a safe and valid therapeutic option for patients with SCCHN who received prior therapy.

关 键 词：TAXANES Immunotherapy Head and neck cancer Alcohol SMOKING Body mass index 

分 类 号：R739.91[医药卫生—肿瘤]